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New active leads for Tuberculosis booster drugs by structure-based 
drug discovery  
Natalie J. Tatuma, John W. Liebeschuetzb, Jason C. Colec, Rosangela Fritad, Adrien 
Herledane, Alain R. Baulardd, Nicolas Willande and Ehmke Pohla,f,g*. 
 
The transcriptional repressor EthR from Mycobacterium tuberculosis, a member of the TetR family of prokaryotic homo-
dimeric transcriptions factors, controls the expression of the mycobacterial mono-oxygenase EthA. EthA is responsible for 
the bio-activation of the second-line tuberculosis pro-drug ethionamide, and consequently EthR inhibitors boost drug 
efficacy. Here, we present a comprehensive in-silico structure-based screening protocol that led to the identification of a 
number of novel scaffolds of EthR inhibitors in subsequent biophysical screening by thermal shift assay. Growth inhibition 
assays demonstrated five of the twenty biophysical hits were capable of boosting ethionamide activity in vitro, with the 
best novel scaffold displaying an EC50 of 34 µM. In addition, the co-crystal structures of EthR with four new ligands at 
resolution ranging from 2.1 to 1.4 Å confirm the binding and inactivation mode, and will enable future lead development.
Introduction 
Tuberculosis remains one of the premier causes of mortality and 
illness, infecting about one third of the world’s population and with 
more than 8 million new cases of disease leading to more than 1.5 
million deaths per year 1. The treatment of Tuberculosis is 
hampered by the pathogen’s ability to remain in a latent, non-
replicating state.2 The problem is exacerbated by the rapid increase 
in multi-drug resistant (MDR) Mycobacterium tuberculosis strains 
that are characterized by showing resistance to the first line drugs 
isoniazid and rifampicin.3 Furthermore, MDR M. tuberculosis strains 
that are also resistant to fluoroquinolone and to an injectable 
second-line antibiotic are classified as extensively drug resistant 
(XDR).4 Whereas first line drugs such as isoniazid, rifampicin, 
pyrazinamide and ethambutol - all developed and in use since the 
1950s and 60s – have been and still are very successful in the DOTS 
(Directly Observed Treatment Short-course) strategy introduced in 
the 1990s, infections with MDR and XDR TB require much more 
extensive treatment with second-line antibiotics including 
fluoroquinolones, D-cycloserine, ethionamide or other antibiotics 
for 2-4 years. These drugs, however, are generally less effective and 
show more often serious side effects.5 For all of these reasons there 
have been renewed efforts in pharmaceutical industry and public 
research institutes to discover and develop new antibiotics.6 While 
target and structure-based approaches such as the Tuberculosis 
Structural Genomics Consortium (TBSGC, htttp://www.webtb.org) 
have contributed great functional knowledge and structural detail 
about key proteins and their interaction partners,7,8 high-
throughput assays based on whole-cells have in general been more 
successful in identifying promising lead compounds.9 Combining all 
efforts has led to more than a dozen compounds, either based on 
known drugs or in some cases new chemical entities that are 
currently in clinical trials.10,11 However, in spite of these 
encouraging recent advances there is an urgent need to optimize 
existing treatments and develop novel therapeutics.5,6  One 
promising strategy developed over the last years focuses on the 
transcriptional regulator EthR, a member of the TetR family 
involved in ethionamide resistance in M. tuberculosis.12,13  
Ethionamide is administered as a pro-drug, which is converted into 
its active NAD adduct inside the mycobacteria by the Bayer-Villiger 
monooxygenase EthA. The NAD-adducts inhibit the 2-trans-enoyl-
acyl carrier protein reductase InhA (Fig. 1), thus interfering with 
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mycolic acid synthesis essential to maintain the pathogen’s cell 
wall.14 
 
Fig. 1: Schematic drawing showing the action of the transcriptional 
regulator EthR on the etha gene. When bound to DNA EthR limits 
the expression of EthA which is responsible for the bioactivation of 
the prodrug forming the active ethionamide-NAD adducts. These 
adducts inhibit the 2-trans-enoyl-acyl carrier protein InhA. 
Based on the discovery that the transcriptional regulator EthR limits 
the expression of EthA, and inhibiting the regulator increases the 
drug action, EthR has been validated as a suitable target for the 
development of compounds that boost the in vitro and in vivo 
efficacy of ethionamide.15 The crystal structures of EthR solved in 
2004, fortuitously both in ligand-bound form, adopt an inactive 
conformation where the DNA-binding domains are orientated such 
to be incompatible to DNA recognition.16,17 Consecutive structure-
based design studies taking advantage of the hydrophobic binding 
pocket led to a series of 1,2,4-oxadiazole inhibitors15,18,19 while high-
throughput screening resulted in the discovery of N-phenoxy 
acetamide derivatives.20 In addition, fragment-based approaches 
were also applied, and through growing, merging and linking 
strategies led to low nanomolar affinity ligands of EthR and low 
nanomolar boosters of ethionamide activity in vitro.21  Moreover, 
Nikiforov et al. showed that hydrophobic piperidinyl amide 
compounds, which were able to inhibit the repressor, filled the 
entire binding pocket.22  
In order to take advantage of the wealth of information hidden in 
the multiple crystal structures of EthR published so far, a high-
throughput in-silico screening strategy was employed starting with 
the ZINC database of available chemical compounds.24 In the past, 
ensemble docking has been suggested where each compound is 
computationally docked in the different protein conformations, 
which can either be derived from a number of crystal structures or 
– albeit less successfully - by molecular dynamics simulation.25,26 
However, firstly the computational costs of this method scales with 
the number of structures and therefore quickly becomes unfeasible, 
and secondly compounds are docked into potentially very similar 
target structures producing a large amount of redundant results. 
Therefore, a target-specific decoy set of molecules was developed 
to select the most suitable EthR crystal structure available in the 
PDB and to optimize the virtual screening parameters. In addition, a 
pre-docking protocol tailored to the unique requirements of the 
protein target was created using the pipeline software KNIME, 
which reduced the number of compounds in the drug-like subset of 
the ZINC database for virtual screening. After high-throughput 
docking using GOLD,27 further detailed post-screening filtering - 
tailored to identify new chemical scaffolds with good starting 
physiochemical properties for development - resulted in a set of 
284 compounds, further reduced to 85 potential hits for biophysical 
analysis by careful manual inspection. Protein-ligand binding was 
measured by thermal shift assay with 20% of virtual screening hits 
showing a significant increase of thermal protein stability. The co-
crystal structures of four compounds, three of which comprise new 
chemical entities for EthR inhibition, were determined to 
resolutions ranging from 1.4 to 2.1 Å. These structures showed that 
in all cases the ligand causes the protein to adopt its inactive 
conformation, confirming the inhibition mechanism. Furthermore, 
detailed analysis of bound compounds led to the identification of 
certain essential binding motifs and allowed a direct comparison of 
computational docking poses and experimental binding mode. 
These results represent the starting point for further lead 
development of tuberculosis booster drugs. 
Results 
Virtual Screening Optimised for EthR - At the time the project was 
started, 12 co-crystal structures of EthR were available in PDB,28 all 
crystallised in the inactive conformation incompatible with DNA 
binding.15-17, 29-31 Despite close similarities in protein arrangement in 
the crystal structures (RMSDs of all Cα-atoms in each monomer 
ranging from 0.2–0.4), distinct differences can be observed in the 
exact ligand positions as shown in Fig. 2.  
Fig. 2: Superposition of the EthR co-crystal structures used in this 
study shown in grey and the different ligands shown as CPK model 
with each color representing one independent structure. Note that 
the left-hand side monomer was used to calculate the 
transformation matrix applied to the EthR dimer. 
Cross-docking was performed to identify the most suitable receptor 
structure. All co-crystallised synthetic ligands were docked into all 
available crystal structures. It is noteworthy that in one case (PDB: 
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1U9N) the key residue Asn179, which forms a highly conserved 
hydrogen bond to the ligands, needed to be manually curated into 
its correct hydrogen bonding pattern. The 25 genetic algorithm runs 
using 1U9N resulted in 150 correct solutions compared to as few as 
less than ten in other cases. Consequently, coordinates from this 
crystal structure were chosen for the virtual screening.  
Compounds were sourced from the Drugs Now subset of the ZINC 
database, a free resource of commercially available chemical 
compounds comprising of 6.06 million compounds (as of 2014 when 
work was undertaken).24 For all compounds in the subset, twenty 
chemical and physicochemical descriptors were calculated (Fig. 3) 
of which several were used for pre-docking filtering using the 
KNIME pipeline software,32  the boundaries of which were based on 
the detailed knowledge of the binding pocket. The most stringent 
filter, excluding approximately 50% of all compounds, restricted the 
compound volume to 200-700 Å2. This decision was taken in spite of 
the fact that the binding pocket extends up to 1100 Å2 in 1U9N to 
focus on smaller, more varied scaffolds which could be devolved 
and further modified in the downstream medicinal chemistry 
efforts. Overall pre-docking filtering reduced the ligand set down to 
approximately 1.3 million compounds (Fig. 3).  
 
 
Fig. 3: Panel a) shows a schematic of the KNIME pipeline used to 
pre-filter compounds for docking. Red boxes indicated input/output 
nodes; green boxes represent calculation nodes; orange boxes 
denote filter nodes with the parameters shown. Panel b) shows the 
chemical descriptors calculated upon the Drugs Now subset, some 
of which were used in pre- and/or post-docking filtering as 
described in the materials and methods section. 
Rhodanines, a class of compounds previously identified as pan-
assay interference (PAINs) compounds that are well known for 
producing false-positives in drug discovery attempts,33 were 
removed and  remaining structures were sorted into 23 groups 
according to chemical ring-system types (see SI: Figure S1 and Table 
S1). Since the resulting cluster sizes range from 8,805 (thiadiazoles) 
to 240,174 (pyrroles), a varying percentage from each cluster was 
taken forward to maintain chemical diversity. The final compound 
cohort for virtual screening comprised of 409,201 structures. 
Parameters for virtual docking were optimized by constructing a 
decoy set of compounds structurally similar to one of the most 
efficacious inhibitors (BDM41906), chosen because crystal 
structures of this compound alone and in complex with EthR have 
been previously determined.18,19 A KNIME pipeline was used to 
select 350 compounds from the ZINC database and create a decoy 
set, applying a set of physicochemical parameters including 
molecular weight and logP,34 with the set used to systematically 
test the docking parameters for screening. The best results as 
measured by highest enrichment of the known ligands within the 
decoy set of 350 compounds were obtained using default genetic 
algorithm parameters implemented in GOLD for 10 runs, maximum 
ligand flexibility and employing the empirical ChemPLP scoring 
function.35  Using the decoy data set, the search efficiency in GOLD 
could be reduced to 20% with a modest search space of radius 10 Å, 
while generating a diverse population of five resultant poses per 
ligand. The decoy set of 350 molecules seeded with 9 known actives 
under these conditions gave enrichment factors of 4.0 - 4.4 at a 
10% cut-off. 
All optimisation experiments were performed on a four processor 
Intel Xeon Desktop, however for expediency, the virtual screening 
itself was conducted on the Darwin Supercomputer at the 
University of Cambridge High Performance Computing facility. With 
409,201 potential ligands in the library and only six compounds that 
failed to generate any docking results, 2,045,975 poses were 
obtained.   
Selection of Virtual Screening Hits – The highest scoring pose for 
each chemical entity was used, and further only the top scoring 10% 
of solutions were carried forward. All descriptors calculated by 
KNIME in pre-filtering were carried forward through screening into 
post-docking filtering. In addition, novel descriptors were 
specifically defined for this binding pocket, such as a requirement 
for a chemically reasonable hydrogen bond geometry with a 
hydrogen bond angle of > 120° (based on the co-crystal structure 
between the ligand and Asn179 as seen for example in PDB entry 
3G1M). Additionally, parameters of the scoring function such as 
clash and torsion terms were used to filter ligands. The range for 
each of the ten parameters used to filter all binding poses of the 
40,919 compounds are summarized in Table 1. This process 
resulted in 284 potential ligands, further evaluated using interactive 
graphics and MOGUL, which uses information from the Cambridge 
Structural Database (CSD) to assess ligand geometries.36 Binding 
poses with highly unusual or unlikely torsion angle and ring 
geometries were manually removed from the hit set intended for 
Page 3 of 13 Organic & Biomolec lar Chemistry
O
rg
an
ic
&
B
io
m
ol
ec
ul
ar
C
he
m
is
tr
y
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
01
 N
ov
em
be
r 2
01
7.
 D
ow
nl
oa
de
d 
by
 D
ur
ha
m
 U
ni
ve
rs
ity
 L
ib
ra
ry
 o
n 
09
/1
1/
20
17
 1
6:
35
:3
4.
 
View Article Online
DOI: 10.1039/C7OB00910K
ARTICLE Journal Name 
4 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
biophysical screening. In addition, chemically similar hits were 
removed in order to reduce redundancies. These steps resulted in 
85 commercially available compounds. The example shown in Fig. 4 
exhibits chemically reasonable ligand geometry and exemplifies key 
interactions of the ligands with the hydrophobic pocket lined by 
Phe110, Phe114, Trp138 and Phe184. In addition, the binding poses 
also show the possible hydrogen bond with the side chain of 
Asn179. The 85 hits were carried forward to biophysical 
characterization. 
Table 1: Details of the parameters used in post-docking filtering to 
derive 284 poses for manual inspection. 
Parameter Range  No. of 
ligands 
CHEMPLP score 10% 40919 
Number of hydrogen bonds with 
angle ≥ 120° 
1 - 6 21949 
Total polar surface area 75 Å2 – 110 
Å2 
15033 
AlogP -3 - 1 5390 
Number of hydrogen bonds formed 
protein:ligand 
1 - 7 25941 
Occluded donor atoms 0 - 1 33603 
Occluded polar atoms 0 - 1 33221 
Ligand clash count 0 - 14 32399 
CHEMPLP ligand torsion score 0.027 – 3.0 28248 
CHEMPLP ligand clash score 0 – 2.0 31950 
Internal energy correction 0 -3.0 20529 
 
 
Fig. 4: Close-up of the ligand binding pocket with the protein shown 
in a grey ribbon representation and compound 64 shown in stick 
representation. Key residues are labelled. 
Identification of Biophysical Hits by Thermal Shift Assay – 
Compounds were sourced from companies ChemBridge, Enamine 
and Ambinter. All compounds were quality-checked by LC-MS and 
or NMR by the company at >95% purity. The complete list is given in 
the ESI. Analytical data (LC-MS/NMR) for the twenty top 
compounds summarized in Table 2 is also presented in the ESI. 
Thermal shift assays, also known as Differential Scanning 
Fluorimetry (DSF) or Thermofluor® assay have been widely used as 
a fast and easy initial biophysical test to verify protein-ligand 
binding.37-39 In almost all cases, ligand binding to a protein target 
causes an increase in thermal stability, although in some cases a 
decrease has also been observed.39 Importantly, TSAs have been 
employed successfully to identify EthR inhibitors from high-
throughput screens20 and to verify EthR-ligand binding of designed 
compounds.22,40  TSAs were performed on all 85 available 
compounds using an optimized protocol in a 96-well-plate format 
(for a complete list see the SI table S2). A typical example of an 
experimental melting curve is shown in Fig. 5a where the addition 
of 80 µM of compound 25 leads to a melting temperature (Tm) of 66 
˚C, which represents a remarkable increase of 9.2˚C indicating 
strong binding. Furthermore, the concentration-dependent change 
of Tm in particular supports the notion of a specific protein-ligand 
interaction (Fig. 5b). In summary, while one compound was 
responsible for a decrease of Tm, 19 out of 85 compounds cause a 
significant increase in Tm. Table 2 lists the Tm of each hit. 
 
 
Fig. 5: Thermal shift assays. Panel a) shows a representative 
example of the experimental fluorescence signal with compound 25 
shown in blue, the first derivative in green and the Tm as a red line. 
Data were analysed using the program NAMI developed in-house39. 
b) Concentration dependent-thermal shifts of the best 20 
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compounds at concentrations of 400, 320, 160 and 80 µM, 
respectively, depicted from left to right in dark green to light green. 
Note, that 85 led to a decrease in thermal stability. 
 
Table 2. Chemical structures and melting temperature of the 20 
potential leads identified by TSAs. 
No Structure ∆Tm 
/˚C 
3 
 
1.4 
4 
 
0.8 
10 
 
2.0 
15 
 
3.5 
17 
 
0.6 
25 
 
9.2 
31 
 
0.7 
42 
 
0.8 
48 
 
0.6 
50 
 
0.6 
56 
 
0.8 
57 
 
6.3 
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58 
 
0.8 
60 
 
6.3 
64 
 
1.3 
72 
 
0.5 
74 
 
0.4 
80 
 
3.5 
84 
 
1.5 
85 
 
-1.6 
 
Growth Inhibition Assays Confirm Several Hits as ETH Boosters – 
Fifteen of the best hit compounds were tested in a growth 
inhibition assay based on fluorescent GFP M. tuberculosis H37Rv 
strains.23 Boosting activity in the presence of ETH at 0.1 µg/mL 
(approximately 20 times lower than the MIC of ETH alone) was 
assessed, with seven compounds demonstrating some boosting 
effect (table 3). The identified boosters include compound 42 and 
compound 25 for which we have solved the co-crystal structures.   
Table 3: Summary of the growth inhibition of M. tuberculosis HR37v 
GFP strains. 
No of compound  EC50 [µM] No of compound  EC50 [µM] 
3 n/a 48 34 
4 n/a 50 > 90 
10 n/a 57 n/a 
15 > 90 60 > 90 
25 0.76 64 n/a 
31 n/a 72 n/a 
42 > 90 84 > 90 
48 34 85 n/a 
50 > 90   
 
Crystal Structures of EthR with Novel Ligands - Crystallization 
experiments were performed with the 20 compounds identified 
through the TSA screen to determine the exact binding mode and 
verify the mechanism of EthR binding and inhibition. Four co-crystal 
structures at high resolution ranging from 1.4-2.1 Å are presented 
here (see SI Table S3 for crystallographic data). As expected all 
crystal structures show the same overall fold of the EthR-
homodimer in the inactive conformation with RMSDs of all Cα-
atoms in one protein monomer ranging from 0.2-0.3 Å. As in all 
previous co-crystal structure determined so far, ligand binding 
appears to lock the protein structure in a conformation where the 
putative DNA-recognition helices are in a relative orientation that 
makes their binding to the major groove as seen in other members 
of the TetR family physically impossible.13   
Structure of EthR with compound 25 – The structure of EthR with N-
butyl-4-methyl-1-piperidine carboxamide was determined at a 
resolution of 1.4 Å (Fig. 6a), which represents the highest resolution 
for any EthR-ligand complex reported so far.  However, this 
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structure represents a serendipitous crystallization event since after 
solving the crystal structure it was discovered that this compound 
was ordered/delivered by mistake and represents a much smaller 
piperidine than originally planned. In fact, with a molecular weight 
of 193 g/mol this compound would have been excluded in the initial 
pre-screening filtering. Nevertheless, the compound contains the 
same basic building blocks and retains the key protein-ligand 
interactions, namely the hydrogen bond to Asn179 (2.8 Å), a second 
hydrogen bond to Asn176 (2.8 Å) and hydrophobic interactions with 
Phe110 and Trp145. Importantly, the carboxamide-piperidine 
moiety occupies the same position as in the EthR-co-crystal 
structure of compound BDM31369 (PDB entry 3Q0V). These results 
show that compound 25 represents an ideal starting point for a 
fragment-growing approach to hit optimization. 
Structure of EthR with compound 10 - The second compound co-
crystallised with EthR, represents a novel scaffold with a central 
carbonyl function flanked by a substituted 1,2-oxazole moiety and a 
substituted 1H, 4H, 5H, 6H-pyrrolo group. The structure was also 
determined at very high resolution showing unambiguously that 
this comparatively large ligand can adopt two distinct orientations, 
each with the occupancy of 50% in the binding site (Fig. 6b). The 
orientation shown in blue (A) maintains the key hydrogen bond to 
Asn179 whereas in the second position (B) shown in yellow the 
carbonyl-function of the ligand forms a hydrogen bond to Thr149. 
Surprisingly, no other potential hydrogen bond donor/acceptor of 
the ligand is involved in protein-ligand interactions and there is no 
space for any water-mediated contacts. Instead both 
crystallographic binding modes appear to be dominated by 
hydrophobic interactions. In orientation A the aliphatic chain of the 
5-propyl-1,2-oxazole is perfectly located in the hydrophobic end of 
the binding pocket composed of residues Leu183, Phe184 and 
Trp138. In contrast, the key interaction in orientation B appears to 
involve hydrophobic stacking of the pyrrolo ring system with 
Phe110. In summary, the crystal structure shows the promiscuity of 
the EthR binding pocket able to accommodate multiple ligand 
binding poses. 
 
 
Fig. 6: Panel a) Close-up of the ligand binding pocket of EthR shown 
in grey ribbon representation co-crystallised with compound 25 
with Carbon bonds shown in magenta, nitrogen in blue, oxygen in 
red. b) Close-up of the ligand-binding pocket of EthR co-crystallised 
with compound 10. The two binding modes are depicted in blue 
and yellow, respectively. 
Structure of EthR with compound 42 – The structure of EthR in 
complex with 1-(3-{5-[(1R,2R)-2-methylcyclopropyl] furan-2-
yl}propanoyl)piperidine-4-carbox-amide was solved to a resolution 
of 1.95 Å (Fig. 7a). This ligand represents the second novel chemical 
scaffold. It is noteworthy that the carbonyl group of the linker does 
not form a hydrogen bond to either Asn176 or Asn179 as one may 
have expected. Presumably this is due to the relatively long linker 
region combined with two ring systems in the hydrophobic pocket.  
In this position the furan ring maintains an optimal position for 
hydrophobic stacking contacts with Phe110 while the 2-
methylcyclopropyl ring is surrounded by Phe114, Leu183, and 
Phe184 respectively. This particular binding mode underlines the 
importance of hydrophobic interactions that can compensate for 
the cost of losing one hydrogen bond. In addition, this structure 
reveals quite important side chain flexibility upon ligand binding 
presumably by an induced fit mechanism.41  
Structure of EthR with compound 57 – The structure of EthR in 
complex with N-[(2R)-2-hydroxy-2-(4-nitrophenyl) ethyl]-2H-1,3-
benzodioxole-5-carboxamide was determined at a resolution of 2.1 
Å (Fig. 7b). This compound induces a particularly high and strongly 
concentration-dependent thermostabilisation of EthR. The ligand 
forms a number of specific hydrogen bonds, which include residues 
Thr149 and Asn176 via its alcohol oxygen in the linker region, and 
Asn179 via the carboxamide carbonyl function. The 1,3-
benzodioxole moiety of the ligand is located as expected in the 
hydrophobic deep end of the binding site with VdW contacts to the 
hydrophobic side chains of residues Leu183, Phe184, and Phe114, 
respectively.  
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Fig. 7: a) Close-up of the ligand-binding pocket of EthR co-
crystallised with compound 42. Phe184 is observable in two 
orientations in the electron density, both are modelled and shown 
in green. b) Close-up of the ligand-binding pocket of EthR co-
crystallised with compound 57.  
Taken together the four crystal structures presented here reveal 
the crucial binding motifs of ligands, provide important information 
about the flexibility of the binding pocket and provide the basis of 
ligand optimization based on new chemical scaffolds. 
Discussions 
Since the early 1980s structure-based drug discovery and design has 
become an important tool in pharmaceutical and academic 
research institutions.42-44 For more and more pharmaceutical 
targets, structural information at atomic resolution based on one or 
– increasingly - several X-ray crystal structures are now available. 
The ever-growing number of relevant PDB entries has been greatly 
supported by the various structural genomics endeavours that had 
drug discovery and design at the core of their aims.7 The 
development of efficient and practical methods to optimally exploit 
the wealth of structural information is therefore crucial. In this 
work we present a computational strategy for filtering the 6.06 
million compounds in the DrugsNow subset of the ZINC database to 
obtain a chemically diverse set of 409,201 compounds tailored to 
the transcriptional regulator EthR. After selecting the most suitable 
protein crystal structure by employing a cross-docking experiment 
with a decoy data set, all compounds were docked into the binding 
site. It is noteworthy that one of the original crystal structures 
fortuitously co-crystallised with hexadecyl octanoate proved most 
receptive to docking presumable due to the fact the binding site 
geometry is not biased through an induced fit by an unnatural 
ligand. Remarkably only six compounds failed to produce any 
computationally feasible binding pose validating the pro-docking 
filtering strategy. A careful post-docking filtering, which included 
clustering the results into 23 different ring chemistries to ensure 
diversity, a shortlist of 284 compounds with five binding poses each 
was obtained. A visual analysis of all binding poses and ligand 
geometries was used in combination with an automatic pipeline 
implementing interactive graphics and tools of GOLDMine, which 
led to a final subset of 85 potential ligands. These in silico hits were 
then evaluated for their capacity to interact with EthR. Twenty 
compounds produced a significant shift in thermal protein stability, 
which provides clear evidence of their binding to EthR 18.  As 
docking scores and binding assays generally show poor correlation, 
the straightforward biophysical characterisation of all compounds 
by thermal shift assays proved essential. 
The co-crystal structures of these four compounds confirm the 
mode of action. Binding of the inhibitor locks the EthR dimer into a 
conformation that is incompatible with DNA binding of the two 
putative DNA-recognition helices in the major grooves of the DNA 
operator. In addition, the high-resolution structures of these new 
chemical scaffolds can be evaluated in the light of the docking 
results, which now suggest new directions for the consecutive 
medicinal chemistry approach. 
Compound 10 – This compound clearly adopts two distinct binding 
modes in the crystal structure as described above. Overall both 
binding modes correspond approximately to two of the predicted 
docking poses. Our more detailed comparison shows that binding 
pose 1 is more closely related to the crystallographic mode A with 
the same hydrogen bonding pattern, whereas 3 and 4 closely 
resemble the second crystallographic position (Fig. 8). These results 
clearly suggest that the scoring function alone is not a sensitive 
predictor of the best binding mode, but that the multiple poses 
obtained by the GA docking algorithm may indicate promiscuity in 
the pocket. Furthermore, the docking poses show that there is 
additional free space in the binding pocket, which opens an obvious 
perspective for further evolution of this ligand. Standard O-
alkylation of the free alcohol function could advantageously 
complete the structure with a methyl, ethyl or isopropyl group, 
filling the hydrophobic space of the binding pocket while 
maintaining the key hydrogen bond to Asn179 revealed by the 
crystallographic binding mode 2. Extending the size on this side of 
the ligand is very likely to render binding mode B energetically less 
favourable. 
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Fig. 8: Superposition of the top five binding poses of compound 10 
(in green) with the two binding modes found in the crystal structure 
depicted in a) blue and b) yellow respectively. 
Compound 42 – In contrast to the previous ligand, compound 42 
adopts a well-defined binding mode, however, somewhat 
surprisingly, the carbonyl oxygen of the central amide linker does 
not form a hydrogen bond to either Asn179 or Asn176 as predicted 
by all of the binding poses and despite at least one ligand-protein 
hydrogen bond being an important criteria the filtering process. 
Docking scores are in the same range as seen for compound 10.  
In the crystal structure the methylcyclopropyl group appears to fill 
the hydrophobic end of the pocket as supported by four out of the 
five binding modes (Fig. 9). In order to maintain these interactions 
while enabling the hydrogen bond of the amide carbonyl oxygen to 
Asn179 (or Asn176) the propanoyl linker needed to be shortened, 
for instance by coupling the piperidine with the corresponding 
activated acyl chloride. 
 
Fig. 9: Superposition of the best five binding poses of compound 42 
(grey) with the binding mode in the crystal structure (magenta). 
Compound 57 – This compound resulted in the highest shift in 
melting temperature with a ∆Tm of 6.3˚C. Two of its binding poses 
correspond to the position found in the crystal structure with pose 
3 being almost identical (Fig. 10).  
The 1,3-benzodioxole moiety seems to fill the hydrophobic end of 
the binding pocket almost perfectly while the amide group is almost 
co-planar to Phe110 providing optimal pi-stacking interactions. The 
carbonyl amide and the free alcohol group of the linker form a 
network of hydrogen bonds to Asn179, Asn176 and Thr149. It is 
likely that these strong ligand-protein interactions are responsible 
for the important thermostabilization of the complex as revealed by 
thermal shift assays. 
 
Fig. 10: Superposition of the best five binding poses of compound 
57 (grey) with the binding mode in the crystal structure (green). 
Biological Activity - Of the fifteen compounds tested five showed 
modest boosting ability in addition to their in-vitro binding. One 
compound, No. 48 demonstrated a promising EC50 value of 34 µM, 
while No. 25 resulted in an EC50 value of 760 nM. Compound 25 is 
of particular interest due to its relatively small size which makes it 
very amenable for elaboration in a medicinal chemistry program. 
Though not identified by the original virtual screening process, this 
compound was subject to the same vigorous biophysical, structural 
and biological tests and immediately recognized to be a perfect 
starting point for further development. Comparing the results of 
thermal shift assays and biological activity shows limited 
correlation, presumably due to differing compound uptake by the 
pathogen. This underlines again the importance of biological assays 
early in the drug discovery pipeline but with such assays in hand, 
the qualities of binding, penetrance and cellular activity can be 
optimised in tandem.  
Conclusions 
In this work, we have developed a robust and versatile 
strategy for in-silico hit discovery based on the ZINC database 
and exploiting the wealth of information in multiple crystal 
structures. Employing tailored pre- and post-docking filtering 
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pipelines that ensured high chemical diversity we identified 20 
new potential candidates for hit optimization. Importantly, this 
pipeline can easily be adapted to other cases where new 
chemical scaffolds are required for structurally well-
characterized target proteins. Given the ever-increasing 
number of high-resolution crystal structures in the PDB, this 
approach will continue to become ever more important. In 
addition, we determined four new co-crystal structures of 
EthR-ligand complexes to resolution of up to 1.4 Å, confirming 
the inhibition mechanism through the opening of the DNA-
binding HTH jaw. The structures reveal the mode of ligand to 
protein binding in atomic detail. Compound 25 presented a 
relatively small molecule with a molecular weight of less than 
200 Da and could thus serve as a perfect starting point for a 
ligand-growing strategy. Compound 10 presented a dual 
binding mode in the crystal structure highlighting the 
challenges for rational drug design in the case of largely 
hydrophobic pockets. Compounds 42 and 57 are probably the 
most promising hits with well-defined binding modes, and in 
the case of 57 exploiting all possible hydrogen bonds in the 
binding pocket.  Finally, biological assays demonstrated that 
six compounds have a modest yet significant boosting effect, 
allowing the future development of cell-penetrant, biologically 
active EthR inhibitors. 
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Three new chemical scaffolds for the inhibition of the transcriptional regulator 
EthR from M. tuberculosis have been identified and verified by biophysical and 
biological assays. 
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